Background: Pancreatic cancer is a highly lethal malignancy with a dismal prognosis, largely due to its insidious onset and difficulty in early detection [2]. Accurate diagnosis and precise staging play a decisive role in formulating therapeutic strategies, particularly given that surgical resection remains the only curative intent option [1]. This report aims to review current medical evidence on pancreatic cancer and present the preliminary results of implementing endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) at 19-8 Hospital.
Literature Review: The review synthesizes data on global epidemiology [2, 3], risk factors [1], screening strategies, and the roles of various imaging modalities. Endoscopic ultrasound (EUS) demonstrates superior accuracy with a sensitivity >90% in detecting small pancreatic lesions < 2cm and providing precise T/N staging [4, 5]. Crucially, EUS-FNB has shifted diagnostic practice from cytology to core histology and comprehensive genomic profiling, establishing the foundation for precision oncology [4, 6].
Preliminary Results: From April 2026 to June 2026, EUS-FNB was successfully performed on 3 patients presenting with solid pancreatic lesions suspicious for malignancy on CT/MRI. Histopathological examination confirmed adenocarcinoma in 02 cases and high-grade epithelial dysplasia in 01 case. Notably, 01 case involved a small pancreatic head tumor 19mm without major vascular invasion, enabling timely surgical referral for pancreaticoduodenectomy (Whipple procedure).
Conclusion: Current medical evidence confirms that EUS-FNB is a safe and highly accurate modality for diagnosing pancreatic cancer [4, 5]. The successful implementation of these initial clinical cases demonstrates technical feasibility at 19-8 Hospital, paving the way for its routine clinical adoption and further comprehensive studies with larger cohorts in the future.